Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective.

Haploidentical family donor is universally available and is fast emerging as an alternative donor choice for children with leukemia needing hematopoietic stem cell transplant (HSCT). Here we describe our experience of treating children with acute leukemia by haploidentical HSCT with posttransplant cyclophosphamide (PTCy). We retrospectively analyzed the outcome data of 17 children with acute leukemia who underwent related haploidentical HSCT. Fifteen were in complete remission (CR) before HSCT: CR1-6, CR2-7, and CR3-2 and 2 were not in remission. Donors were mobilized with granulocyte colony stimulating factor. The conditioning was nonmyeloablative in 4 and myeloablative in 13. All received PTCy 50 mg/kg on days 3 and 4 as graft-versus-host disease (GVHD) prophylaxis along with tacrolimus or cyclosporine and mycophenolate mofetil. A median of 8.94 million of CD34+ cells/kg was infused. All patients were engrafted for neutrophil and platelets, except 1 child with refractory acute myeloid leukemia disease who relapsed before engraftment. Five children relapsed (4 died and 1 child with CD20-positive leukemia is disease free after Rituximab therapy). There was 1 transplant-related mortality due to grade IV GVHD. Remaining 11 patients are in CR. Acute GVHD was seen in 4 patients. Of 4, 3 children later developed chronic GVHD and all are alive and disease free. Three of 4 children who received nonmyeloablative conditioning have relapsed. Overall survival is 70.5% and event-free survival is 64.7%. Median follow-up of all patients was 393 days. Haploidentical HSCT with PTCy is a safe and effective therapy for children with acute leukemia. Myeloablative conditioning and chronic GVHD lead to improved disease-free survival.

Sharma A ，Rastogi N ，Chatterjee G ，Kapoor R ，Nivargi S ，Yadav SP ... -  《-》

Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplanta

Nagler A ，Labopin M ，Houhou M ，Aljurf M ，Mousavi A ，Hamladji RM ，Al Zahrani M ，Bondarenko S ，Arat M ，Angelucci E ，Koc Y ，Gülbas Z ，Sica S ，Bourhis JH ，Canaani J ，Brissot E ，Giebel S ，Mohty M ... -  《Journal of Hematology & Oncology》

Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a singl

Lu Y ，Zhao YL ，Zhang JP ，Xiong M ，Cao XY ，Liu DY ，Sun RJ ，Wei ZJ ，Zhou JR ，Lu DP ... -  《-》

T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.

Sano H ，Mochizuki K ，Kobayashi S ，Ohara Y ，Ito M ，Waragai T ，Takahashi N ，Ikeda K ，Ohto H ，Kikuta A ... -  《-》

Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transpla

Bazarbachi AH ，Labopin M ，Raiola AM ，Blaise D ，Arcese W ，Santarone S ，Koc Y ，Bramanti S ，Kulagin A ，Kwon M ，Sica S ，Sanz J ，Brissot E ，Nagler A ，Ciceri F ，Mohty M ... -  《-》